First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the ...

New research appearing in the journal Nature Biotechnology answers important questions about the viability of treatments that seek to replace diseased and aged cells in the central nervous system with ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

A study released in December of 2024 has found that drones not only can provide rural residents with access to healthcare resources, but that rural people are eager to embrace the new technology.

You will have a wide range of opportunities for career preparation directly related to your field of study, all of which provide hands-on experiences that turn knowledge into know-how.

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...